BIOTECHNOLOGY
SYSTEMS
BRANCH

RAW SEQUENCE LISTING
ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information
Center (STIC) detected errors when processing the following computer readable
form:

Application Serial Number: 09/851,422

Source: /600

Date Processed by STIC: 7/2/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:
1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE
   APPLICANT, WITH A NOTICE TO COMPLY or,
2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A
   NOTICE TO COMPLY
FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.
 PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)
 PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER
VERSION 3.1 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:
       http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is
a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.
Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the
United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm> , EFS Submission
   User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
   U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
    Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
            Or
   U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
   2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,
   Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

RECEIVED

JUL 0 8 2002

TECH CENTER 1600/2900

1600

#12

Does Not Comply

Corrected Diskette Needed

RAW SEQUENCE LISTING   DATE: 07/02/2002
PATENT APPLICATION: US/09/851,422   TIME: 14:19:58

Input Set : A:\35879122.app
Output Set: N:\CRF3\07022002\I851422.raw

```
 3 <110> APPLICANT: YU, XIANXHANG
 4        WAGNER, THOMAS E.
 6 <120> TITLE OF INVENTION: THERAPEUTIC PORE-FORMING PEPTIDES
 8 <130> FILE REFERENCE: 035879/0122
10 <140> CURRENT APPLICATION NUMBER: 09/851,422
11 <141> CURRENT FILING DATE: 2001-05-09
13 <150> PRIOR APPLICATION NUMBER: 60/203,063
14 <151> PRIOR FILING DATE: 2000-05-09
16 <150> PRIOR APPLICATION NUMBER: 60/212,042
17 <151> PRIOR FILING DATE: 2000-06-16
19 <160> NUMBER OF SEQ ID NOS: 12
21 <170> SOFTWARE: PatentIn Ver. 2.1
23 <210> SEQ ID NO: 1
24 <211> LENGTH: 37
25 <212> TYPE: PRT
26 <213> ORGANISM: Artificial Sequence
28 <220> FEATURE:
29 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
30        peptide
32 <220> FEATURE:
33 <221> NAME/KEY: MOD_RES
34 <222> LOCATION: (10)..(13)
35 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon
36        -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
37        -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
38        -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
40 <220> FEATURE:
41 <221> NAME/KEY: MOD_RES
42 <222> LOCATION: (22)..(25)
43 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon
44        -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
45        -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
46        -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
48 <220> FEATURE:
49 <221> NAME/KEY: MOD_RES
50 <222> LOCATION: (34)..(37)
51 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon
52        -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
53        -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
54        -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
56 <220> FEATURE:
```

57 <223> OTHER INFORMATION: This molecule may encompass smaller embodiments according
58   to the application as filed

RAW SEQUENCE LISTING   DATE: 07/02/2002
PATENT APPLICATION: US/09/851,422 TIME: 14:19:58

Input Set : A:\35879122.app
Output Set: N:\CRF3\07022002\I851422.raw

```
     60 <400> SEQUENCE: 1
W--> 61 Gly Phe Ile Ala Thr Leu Cys Thr Lys Xaa Xaa Xaa Xaa Val Leu Asp
     62   1               5                  10                  15
W--> 64 Phe Gly Ile Asp Lys Xaa Xaa Xaa Xaa Leu Ile Gln Leu Ile Glu Asp
     65                20                  25                  30
W--> 67 Lys Xaa Xaa Xaa Xaa
     68           35
     71 <210> SEQ ID NO: 2
     72 <211> LENGTH: 38
     73 <212> TYPE: PRT
     74 <213> ORGANISM: Artificial Sequence
     76 <220> FEATURE:
     77 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     78       peptide
     80 <220> FEATURE:
     81 <221> NAME/KEY: MOD_RES
     82 <222> LOCATION: (8)..(11)
     83 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon
     84       -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
     85       -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
     86       -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
     88 <220> FEATURE:
     89 <221> NAME/KEY: MOD_RES
     90 <222> LOCATION: (26)..(29)
     91 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon
     92       -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
     93       -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
     94       -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
     96 <220> FEATURE:
     97 <221> NAME/KEY: MOD_RES
     98 <222> LOCATION: (32)..(35)
     99 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon
    100       -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
    101       -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
    102       -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
    104 <220> FEATURE:
    105 <223> OTHER INFORMATION: This molecule may encompass smaller embodiments according
    106       to the application as filed
    108 <400> SEQUENCE: 2
W--> 109 Gly Ile Gly Ala Val Leu Lys Xaa Xaa Xaa Xaa Val Leu Thr Thr Gly
    110   1               5                  10                  15
W--> 112 Leu Pro Ala Leu Ile Ser Trp Ile Lys Xaa Xaa Xaa Xaa Arg Lys Xaa
    113                20                  25                  30
W--> 115 Xaa Xaa Xaa Arg Gln Gln
    116           35
    119 <210> SEQ ID NO: 3
    120 <211> LENGTH: 25
    121 <212> TYPE: PRT
    122 <213> ORGANISM: Entamoeba histolytica
```

```
                    RAW SEQUENCE LISTING              DATE: 07/02/2002
                    PATENT APPLICATION:  US/09/851,422  TIME: 14:19:58

                    Input Set : A:\35879122.app
                    Output Set: N:\CRF3\07022002\I851422.raw

124 <400> SEQUENCE: 3
125 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
126   1             5                 10                15
128 Lys Leu Ile Gln Leu Ile Glu Asp Lys
129            20                25
132 <210> SEQ ID NO: 4
133 <211> LENGTH: 37
134 <212> TYPE: PRT
135 <213> ORGANISM: Antheraea pernyi
137 <220> FEATURE:
138 <223> OTHER INFORMATION: Cecropin A
140 <400> SEQUENCE: 4
141 Lys Trp Lys Leu Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile Arg
142   1             5                 10                15
144 Asp Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln Ala
145            20                25                30
147 Thr Gln Ile Ala Lys
148          35
151 <210> SEQ ID NO: 5
152 <211> LENGTH: 35
153 <212> TYPE: PRT
154 <213> ORGANISM: Antheraea pernyi
156 <220> FEATURE:
157 <223> OTHER INFORMATION: Cecropin B
160 <400> SEQUENCE: 5
161 Lys Trp Lys Ile Phe Lys Lys Ile Glu Lys Val Gly Arg Asn Ile Arg
162   1             5                 10                15
164 Asn Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Leu Gly Glu Ala
165            20                25                30
167 Lys Ala Leu
168          35
171 <210> SEQ ID NO: 6
172 <211> LENGTH: 36
173 <212> TYPE: PRT
174 <213> ORGANISM: Antheraea pernyi
176 <220> FEATURE:
177 <223> OTHER INFORMATION: Cecropin D
179 <400> SEQUENCE: 6
180 Trp Asn Pro Phe Lys Glu Leu Glu Lys Val Gly Gln Arg Val Arg Asp
181   1             5                 10                15
183 Ala Val Ile Ser Ala Gly Pro Ala Val Ala Thr Val Ala Gln Ala Thr
184            20                25                30
186 Ala Leu Ala Lys
187          35
190 <210> SEQ ID NO: 7
191 <211> LENGTH: 26
192 <212> TYPE: PRT
193 <213> ORGANISM: Apis mellifera
195 <400> SEQUENCE: 7
```

```
              RAW SEQUENCE LISTING                 DATE: 07/02/2002
              PATENT APPLICATION:  US/09/851,422   TIME: 14:19:58

              Input Set : A:\35879122.app
              Output Set: N:\CRF3\07022002\I851422.raw

196 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
197   1             5               10              15
199 Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
200              20              25
203 <210> SEQ ID NO: 8
204 <211> LENGTH: 27
205 <212> TYPE: PRT
206 <213> ORGANISM: Artificial Sequence
208 <220> FEATURE:
209 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
210       peptide
212 <220> FEATURE:
213 <221> NAME/KEY: MOD_RES
214 <222> LOCATION: (26)..(27)
215 <223> OTHER INFORMATION: [epsilon-gamma]-Glu-[alpha-gamma]-Glu
217 <400> SEQUENCE: 8
218 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
219   1             5               10              15
221 Lys Leu Ile Gln Leu Ile Glu Asp Lys Xaa Xaa
222              20              25
225 <210> SEQ ID NO: 9
226 <211> LENGTH: 26
227 <212> TYPE: PRT
228 <213> ORGANISM: Artificial Sequence
230 <220> FEATURE:
231 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
232       peptide
234 <220> FEATURE:
235 <221> NAME/KEY: MOD_RES
236 <222> LOCATION: (26)
237 <223> OTHER INFORMATION: [epsilon-alpha]-Phe
239 <400> SEQUENCE: 9
240 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
241   1             5               10              15
243 Lys Leu Ile Gln Leu Ile Glu Asp Lys Xaa
244              20              25
247 <210> SEQ ID NO: 10
248 <211> LENGTH: 27
249 <212> TYPE: PRT
250 <213> ORGANISM: Artificial Sequence
252 <220> FEATURE:
253 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
254       peptide
256 <220> FEATURE:
257 <221> NAME/KEY: MOD_RES
258 <222> LOCATION: (18)
259 <223> OTHER INFORMATION: [epsilon-alpha]-Phe
261 <220> FEATURE:
262 <221> NAME/KEY: MOD_RES
```

RAW SEQUENCE LISTING   DATE: 07/02/2002
PATENT APPLICATION: US/09/851,422   TIME: 14:19:58

Input Set : A:\35879122.app
Output Set: N:\CRF3\07022002\I851422.raw

```
263 <222> LOCATION: (27)
264 <223> OTHER INFORMATION: [epsilon-alpha]-Phe
266 <400> SEQUENCE: 10
267 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
268  1               5                   10                  15
270 Lys Xaa Leu Ile Gln Leu Ile Glu Asp Lys Xaa
271              20                  25
274 <210> SEQ ID NO: 11
275 <211> LENGTH: 28
276 <212> TYPE: PRT
277 <213> ORGANISM: Artificial Sequence
279 <220> FEATURE:
280 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
281       peptide
283 <220> FEATURE:
284 <221> NAME/KEY: MOD_RES
285 <222> LOCATION: (22)
286 <223> OTHER INFORMATION: [epsilon-gamma]-Glu
288 <220> FEATURE:
289 <221> NAME/KEY: MOD_RES
290 <222> LOCATION: (25)
291 <223> OTHER INFORMATION: [epsilon-gamma]-Glu
293 <400> SEQUENCE: 11
294 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
295  1               5                   10                  15
297 Ile Ser Trp Ile Lys Xaa Arg Lys Xaa Arg Gln Gln
298              20                  25
301 <210> SEQ ID NO: 12
302 <211> LENGTH: 30
303 <212> TYPE: PRT
304 <213> ORGANISM: Artificial Sequence
306 <220> FEATURE:
307 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
308       peptide
310 <220> FEATURE:
311 <221> NAME/KEY: MOD_RES
312 <222> LOCATION: (19)..(20)
313 <223> OTHER INFORMATION: [epsilon-gamma]-Glu-[alpha-gamma]-Glu
315 <220> FEATURE:
316 <221> NAME/KEY: MOD_RES
317 <222> LOCATION: (23)..(24)
318 <223> OTHER INFORMATION: [epsilon-gamma]-Glu-[alpha-gamma]-Glu
320 <400> SEQUENCE: 12
321 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
322  1               5                   10                  15
324 Ile Ser Trp Ile Lys Xaa Xaa Arg Lys Xaa Xaa Arg Gln Gln
325              20                  25                  30
```

[Handwritten annotations:]

wal

Ov-->

"Trp" is at location 19 and "Ile" is at location 20

what about Xaa at location 22?

"Arg" is at location 24

W-->

what about Xaa's at location 26 and 27?

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: **US/09/851,422**

DATE: 07/02/2002
TIME: 14:19:59

Input Set : **A:\35879122.app**
Output Set: **N:\CRF3\07022002\I851422.raw**

Please Note:
Use of **n** and/or **Xaa** have been detected in the Sequence Listing. Please review the
Sequence Listing to ensure that a corresponding explanation is presented in the <220>
to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 10,11,12,13,22,23,24,25,34,35,36,37
Seq#:2; Xaa Pos. 8,9,10,11,26,27,28,29,32,33,34,35
Seq#:8; Xaa Pos. 26,27
Seq#:9; Xaa Pos. 26
Seq#:10; Xaa Pos. 18,27
Seq#:11; Xaa Pos. 22,25
Seq#:12; Xaa Pos. 22,23,26,27